Abstract Body

Background:

Outbreaks typically occur when a pathogen is introduced into a population with little or no immunity. The 2022 mpox outbreak among men-who-have-sex-with-men (MSM) was a good example. In the Netherlands, smallpox vaccination ended in 1974. During summer of 2022, MSM who engage in high-risk sexual behavior were offered vaccination with the Imvanex vaccine. In September 2022, at the end of the outbreak, we measured an IgG seroprevalence against MPXV of 45% among MSM visiting the Center for Sexual Health in Rotterdam. Our study aims to predict whether the current seroprevalence levels can prevent future mpox outbreaks.

Methods:

A modified stochastic SEIR model was developed. The model stratifies individuals based on vaccination status (unvaccinated, historically smallpox vaccinated and newly Imvanex vaccinated). Using literature estimates, vaccination is assumed to reduce infectiousness by 85% (range 75-95%) and 86% (83-90%) for historical and new vaccinations, respectively. Upon infection, individuals progress to an incubation period (4-12 days) and an infectious period (1-21 days). In our model, re-infections cannot occur. We assume that the outbreak was started by a super spreading event resulting in 15-100 initial infections. We calibrated the model to the exponential phase of the 2022 mpox outbreak in the Netherlands and to the total number of individuals (1,200-1,800), who were infected 120-180 days after the outbreak started. A new outbreak was modelled at a seroprevalence of at least 45% using all parameters and values from the calibrated model. The total number of infections was calculated as the number of secondary cases, excluding the initial infections starting the outbreak.

Results:

The size and duration of a new mpox outbreak strongly decreased with increasing seroprevalence. At a seroprevalence of 45-55%, the average outbreak size was 108 cases (interquartile range, IQR, 60-147), with a peak after an average of 52 days (IQR 33–68). A seroprevalence of 70% would result in a further decrease to 20 cases (IQR 0-90) and a peak after 28 days (IQR 21-40), respectively. A new outbreak was unlikely at a seroprevalence of at least 85%.

Conclusions:

Using stochastic modelling, we predict that increased seroprevalence during 2022 (by vaccination or infection) would strongly reduce the size and duration of future mpox outbreaks among MSM. Our findings emphasize the importance of vaccine-induced immunity in risk groups to prevent future outbreaks.